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Abstract
Purpose Obstructive sleep apnoea (OSA) represents a risk for dyslipidaemia. Obstructive respiratory events during rapid 
eye movement (REM) sleep are more strongly related to the development of hypertension and diabetes than in non-REM. 
However, the relationship between sleep phases and serum lipid profile is unclear. We aimed to analyse the relationship 
between obstructive respiratory events in REM and non-REM sleep as well as serum lipid profile.
Methods Polysomnography was performed in 94 adult subjects who did not take any lipid-modifying medications. Fasting 
venous blood sample was taken the following morning for total cholesterol, triglyceride, high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol, lipoprotein(a), apoprotein A1 (ApoA1) and for apoprotein B (ApoB) measure-
ments. Lipid profiles were correlated with apnoea–hypopnoea index (AHI) during REM  (AHIREM) and non-REM  (AHINREM) 
stages in all subjects. In addition, lipid profiles were compared between REM-dependent OSA patients  (AHIREM ≥ 5/h, but 
 AHINREM < 5/h) and control subjects (both  AHIREM and  AHINREM < 5/h).
Results AHIREM correlated only with triglyceride concentrations (p = 0.04, Spearman’s rho, ρ = 0.21). In contrast, there was 
a significant association between  AHINREM and triglyceride (p = 0.02, ρ = 0.23), ApoB (p = 0.03, ρ = 0.21), HDL-C (p < 0.01, 
ρ = − 0.32) as well as ApoA1 levels (p = 0.04, ρ = − 0.21). However, these correlations were not present after adjustment 
for BMI (all p > 0.05). There was no difference in the lipid profile of REM-dependent OSA subjects and healthy controls 
(p > 0.05).
Conclusions Altered serum lipid profile is equally associated with a disturbed REM and non-REM sleep in OSA. Obesity 
must be considered as a strong covariate when interpreting lipid data in sleep apnoea.
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Introduction
Obstructive sleep apnoea (OSA) is a common disorder 
which is characterised by the repetitive episodes of total or 
partial collapse of pharynx leading to intermittent hypoxia 
and frequent micro-arousals. On one hand, patients with 
OSA commonly report daytime sleepiness and impaired 
performance in daily activities. On the other hand, this dis-
order is associated with the development and worsening of 
cardiovascular and cognitive diseases as well as metabolic 
dysfunction [1] such as dyslipidaemia [2, 3].
Dyslipidaemia is a major risk factor in the development 
of cardiovascular diseases [4]. Although traditionally, total 
cholesterol, low-density lipoprotein cholesterol (LDL-C), 
high-density lipoprotein cholesterol (HDL-C) and triglycer-
ide (TG) are the main lipid components measured in clinical 
practice, guidelines recommend the analysis of additional 
components including apoprotein A1 (ApoA1), apoprotein 
B (ApoB) and lipoprotein(a) (LPA) when assessing dyslipi-
daemia [4]. Dyslipidaemia is highly prevalent in OSA [5] 
and large cohort studies showed elevated total cholesterol 
and TG as well as lowered HDL-C levels [6, 7].
Chronic intermittent hypoxia and fragmented sleep 
architecture contribute to dyslipidaemia independently [1]. 
Chronic intermittent hypoxia blocks lipoprotein lipase via 
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hypoxia-inducible factor leading to increased levels of TG 
[1]. Furthermore, inflammation and oxidative stress in OSA 
result in altered structure of visceral white adipose tissue [8]. 
Of note, sleep fragmentation increases adipocyte number 
and size [1]. OSA also shifts appetite towards increased con-
sumption of fat and carbohydrate by reducing the concentra-
tion of leptin and elevating the level of ghrelin in plasma [1, 
9]. An increase in sympathetic activity, a consequence of 
hypoxia and micro-arousals may liberate cholesterol and TG 
from adipocytes [10]. Moreover, oxidative stress burden in 
OSA accelerates the development of cardiovascular disease 
related to lipid dysfunction [3]. Finally, OSA induces altera-
tions in the production of thyroid [11] and growth hormones 
[12], which influence lipid metabolism.
Recent evidence suggests that the association between 
OSA and the development of comorbidities, such as cardio-
vascular disease [13], hypertension [14–16], atherosclerosis 
[17, 18] and diabetes [19], strongly depends on the num-
ber of apnoeic events and desaturations during rapid eye 
movement (REM) sleep. It is known that the production of 
growth hormone (GH), cortisol or thyroid hormones during 
night shows variability between REM or non-REM sleep 
[11, 20]. In addition, compared to non-REM sleep, REM 
sleep is characterised by higher sympathetic tone [21] in all 
subjects and longer apnoeic periods as well as greater oxy-
gen desaturations in patients with OSA [22]. As hypoxia and 
augmented sympathetic activity may exaggerate dyslipidae-
mia [3], one would expect that REM sleep-related obstruc-
tive respiratory events induce more prominent changes in the 
lipid profile compared to the non-REM sleep. However, this 
has not been investigated before.
Therefore, the aim of our study was to analyse the rela-
tionship between obstructive respiratory events during REM 
and non-REM sleep on the lipid profile.
Methods
Study Design and Subjects
Ninety-four adult volunteers were recruited for the 
study [49 ± 16 years, 30 men, body mass index (BMI) of 
26.4 ± 5.2 kg/m2]. 13 subjects (14%) were current or ex-
smokers, 41 (44%) volunteers had hypertension and 12 
(13%) were treated with diabetes. Subjects taking any anti-
lipid treatment, including statins, fibrates or nicotinic acid, 
being on ketogenic diet and those with known primary dys-
lipidaemia were excluded. None of the patients had been 
diagnosed with OSA and had not used continuous positive 
airway pressure (CPAP) or oral appliance device.
After taking medical history and filling out the Epworth 
sleepiness scale (ESS), subjects attended a full-night poly-
somnography. The following morning, fasting venous blood 
was collected for C-reactive protein (CRP), total cholesterol, 
TG, HDL-C, LDL-C, LPA, ApoA1 as well as ApoB meas-
urements before taking any medications.
The study was approved by the local Ethics Committee 
(Semmelweis University, TUKEB 30/2014) and informed 
consent was obtained from all participating volunteers. The 
study was conducted according to the Declaration of Hel-
sinki (as revised in Brazil 2013).
Polysomnography
Polysomnography was performed as described previously 
[23] using SOMNOscreen Plus Tele PSG (SOMNOmed-
ics GMBH Germany). Briefly, electroencephalogram, elec-
trooculogram and electromyogram, thoracic and abdomi-
nal respiratory excursions, breath sounds, nasal pressure, 
electrocardiogram and oxygen saturation were registered 
[24]. Sleep stages, movements and cardiopulmonary events 
were scored manually according to the American Academy 
of Sleep Medicine (AASM) guidelines [25]. Total sleep 
time (TST), sleep period time (SPT), percentage of total 
sleep time spent in rapid eye movement stage (REM%), 
percentage of total sleep time spent with saturation below 
90% (TST90%) and minimal  O2 saturation  (minSatO2) 
were recorded; Apnoea-hypopnoea index (AHI), oxygen 
desaturation index (ODI) and arousal index (AI) were cal-
culated. AHI was evaluated both during REM  (AHIREM) and 
non-REM  (AHINREM) sleep. Obstructive sleep apnoea was 
defined as having an AHI ≥ 5/h, while REM-dependent OSA 
as having an  AHIREM ≥ 5/h, but  AHINREM < 5/h.
Statistical Analysis
Statistica 12 (StatSoft, Inc., Tulsa, OK) software was used 
for statistical analysis. Data normality was tested with the 
Kolmogorov–Smirnov’s test. Categorical parameters were 
compared with Chi-square test. Lipid profile was compared 
between the OSA and non-OSA groups (AHI < 5/h) as 
well REM-dependent OSA and controls (both  AHIREM and 
 AHINREM < 5/h) using the Mann–Whitney test. The Spear-
man’s test was used to correlate lipids with clinical param-
eters. The effects of BMI, age and gender as co-variates were 
assessed with multivariate analyses and the general mixed 
linear model. A p value < 0.05 was considered statistically 
significant.
Results
Patient Characteristics
Following polysomnography, the volunteers were divided 
into OSA (n = 41) and non-OSA (n = 53) groups. Patients 
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with OSA were classified into mild (AHI 5–14.9 events/h, 
n = 21), moderate (AHI 15–29.9 events/h, n = 13) and severe 
(AHI > 30 events/h, n = 7) subgroups. The patients were sig-
nificantly older, had higher BMI, had higher prevalence of 
males and hypertension (all p < 0.05). They also had longer 
total sleep time and sleep period time, higher AHI, ODI, 
TST90% and lower  MinSatO2 (all p < 0.05). There was no 
difference in the prevalence of smokers or patients with 
diabetes, CRP, ESS, REM% or AI (all p > 0.05) between 
the two groups. Subjects’ characteristics are summarised in 
Table 1.
The Lipid Profile in the OSA and Control Groups
Serum triglyceride and ApoB levels were higher, while 
serum HDL-C levels were lower in OSA (all p < 0.05). 
There was a trend for lower ApoA1 concentrations in OSA 
(p = 0.07). There was no difference in total cholesterol, 
LDL-C or LPA between the two groups (p > 0.05, Table 1). 
Correlation between the elements of lipid profile and clinical 
variables is shown in Table 2.
Differences in serum triglyceride, ApoB and HDL-C 
levels between OSA and control groups were adjusted for 
BMI, age and gender. After adjustment for BMI, the differ-
ences between the two groups for the three lipid parameters 
became insignificant (all p > 0.05). Adjustment for male gen-
der significantly affected the difference in HDL-C, while 
adjustment for age did not influence any of the inter-group 
differences.
Relationship Between Lipid Profile and  AHIREM 
as well as  AHINREM
There was a significant correlation between  AHIREM and TG 
levels (p = 0.04, ρ = 0.21, Fig. 1a), but not with any other 
lipid components (Fig. 2a). In contrast,  AHINREM correlated 
directly with TG (p = 0.02, ρ = 0.23, Fig. 1b) and ApoB 
(p = 0.03, ρ = 0.22), and indirectly with HDL-C (p < 0.01, 
ρ = − 0.32, Fig. 2b) and ApoA1 (p = 0.04, ρ = − 0.21).
Adjusting for BMI, all the relationships above became 
insignificant (p > 0.05). After adjustment for male gender 
the relationships between  AHINREM and ApoA1, ApoB and 
HDL-C became insignificant, but this did not affect the asso-
ciations between TG and  AHIREM or  AHINREM. Adjustment 
for age did not affect the relationship between  AHIREM and 
TG,  AHINREM and TG as well as  AHINREM and HDL-C.
Differences Between REM‑Dependent OSA 
and Control Groups
From all volunteers, 16 were diagnosed with REM-depend-
ent OSA. Their lipid profile was compared with control 
subjects (n = 39). There was no difference in any of the 
investigated lipid parameters (all p > 0.05, data not shown).
Discussion
In this study, we evaluated the relationship between obstruc-
tive respiratory events during REM versus non-REM sleep 
and lipid profile. We found that TG levels related to AHI 
irrespective of REM or non-REM phase, while HDL-C, 
ApoA1 and ApoB were associated with AHI only during 
non-REM stage. In contrast to cardiovascular disease, hyper-
tension and diabetes, the presence of dyslipidaemia in OSA 
Table 1  Subject’s characteristics
The data are expressed as mean ± standard deviation for parametric 
and median (range) for non-parametric variables. Significant differ-
ences are presented in bold
BMI body mass index, CRP C-reactive protein, HDL-C high-density 
lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, 
TG triglyceride, ApoA1 apolipoprotein A1, ApoB apolipoprotein 
B, LPA lipoprotein (a), TST total sleep time, SPT sleep period time, 
REM% percentage of total sleep time spent in rapid eye movement 
stage, AHI apnoea–hypopnoea index, ODI oxygen desaturation index, 
TST90% percentage of total sleep time spent with saturation below 
90%, MinSatO2 minimal  O2 saturation, AI arousal index
Control (n = 53) OSA (n = 41) p Value
Gender (male/
female)
12/41 18/23 0.02
Age (years) 45 (20–74) 60 (29–74) < 0.01
BMI (kg/m2) 24.6 ± 3.6 28.7 ± 6.1 < 0.01
Hypertension (%) 21 61 < 0.01
Diabetes (%) 17 9 0.27
Smokers (%) 20 9 0.16
Epworth sleepiness 
scale
6 (1–14) 6 (0–14) 0.62
CRP (mg/ml) 1.8 (0.2–73.2) 2.3 (0.2–49.5) 0.58
Total cholesterol 
(mmol/l)
5.30 (3.50–8.50) 5.40 (3.40–8.50) 0.73
HDL-C (mmol/l) 1.72 (0.79–3.74) 1.48 (0.88–5.97) < 0.01
LDL-C (mmol/l) 3.03 (1.09–5.43) 3.11 (1.36–5.57) 0.50
TG (mmol/l) 1.00 (0.42–3.99) 1.34 (0.65–4.16) < 0.01
ApoA1 (g/l) 1.62 (0.00–2.10) 1.51 (0.84–2.29) 0.07
ApoB (g/l) 1.06 (0.45–3.22) 1.23 (0.69–2.12) 0.04
LPA (g/l) 0.12 (0.00–1.13) 0.31 (0.00–1.13) 0.32
TST (min) 383 ± 57 412 ± 35 < 0.01
SPT (min) 418 ± 50 447 ± 36 < 0.01
REM% 15.6 ± 7.0 16.3 ± 6.7 0.64
AHI (1/h) 2.3 (0.0–4.8) 14.6 (5.0–126.5) < 0.01
ODI (1/h) 0.9 (0.0–4.3) 11.3 (1.5–120.60) < 0.01
TST90% 1.5 ± 6.7 7.9 ± 19.5 < 0.01
MinSatO2 90.7 ± 3.3 83.0 ± 8.4 < 0.01
AI (1/h) 46.8 ± 20.1 47.0 ± 20.8 0.91
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may not be influenced by the timely occurrence of respira-
tory events.
The need for biomarkers which predict OSA-related 
mortality has been emphasised [26], and the measurement 
of serum lipids may have additional clinical value when 
predicting long-term consequences such as cardiovascular 
morbidity and mortality. Dyslipidaemia is a major factor 
in the development of cardiovascular diseases, and OSA 
is associated with altered lipid profile. According to the 
European Society of Cardiology/European Atherosclerosis 
Society, dyslipidaemia should be evaluated based on the 
profile of multiple lipids and lipoproteins [4]. The meas-
urement of apoA1 and apoB have advantages over con-
ventional analyses of lipids, namely, that the assays do 
not require fasting conditions and are not influenced by 
high TG levels [4]. ApoB is the major constituent of the 
atherogenic lipoproteins, such as LDL, very low-density 
lipoprotein and intermediate density lipoprotein, while 
apoA1 is the main component of HDL. Despite the afore-
mentioned methodological advantage, it seems that the 
Table 2  Relationships between serum lipid levels and clinical variables
Spearman’s rho are presented for significant relationships in bold. Non-significant associations are marked as NS
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, ApoA1 apolipoprotein A1, ApoB apoli-
poprotein B, LPA lipoprotein (a), BMI body mass index, CRP C-reactive protein, ESS Epworth sleepiness scale, TST total sleep time, SPT sleep 
period time, REM% percentage of total sleep time spent in rapid eye movement stage, AHI apnoea–hypopnoea index, ODI oxygen desaturation 
index, TST90% percentage of total sleep time spent with saturation below 90%, MinSatO2 minimal  O2 saturation, AI arousal index
Total cholesterol 
(mmol/l)
HDL-C (mmol/l) LDL-C (mmol/l) TG (mmol/) ApoA1 (g/l) ApoB (g/l) LPA (g/l)
Gender (male) NS − 0.46 NS 0.25 − 0.32 NS NS
Age (years) 0.28 NS NS 0.23 NS 0.23 NS
BMI (kg/m2) 0.21 − 0.42 0.33 0.49 NS 0.32 NS
Hypertension NS − 0.26 NS 0.42 NS NS NS
Diabetes NS NS NS 0.27 NS 0.31 NS
Smoker NS NS NS NS NS NS NS
ESS NS NS NS 0.26 NS NS NS
CRP (mg/ml) 0.33 − 0.27 0.36 0.35 NS 0.46 NS
TST (min) NS NS NS 0.31 NS NS NS
SPT (min) NS NS NS NS NS NS NS
REM% NS NS NS NS NS NS NS
AHI (1/h) NS − 0.29 NS 0.26 NS 0.21 NS
ODI (1/h) NS − 0.38 NS 0.39 NS 0.29 NS
TST90% 0.25 − 0.23 0.22 0.35 NS 0.29 NS
MinSatO2 − 0.29 0.31 − 0.33 − 0.37 NS − 0.31 NS
AI (1/h) NS NS − 0.24 NS NS NS NS
Fig. 1  Relationship between serum triglyceride levels and  AHIREM (a) as well as  AHINREM (b). There was a significant correlation between TG 
levels and  AHIREM (p = 0.04, ρ = 0.21, a) and  AHINREM (p = 0.02, ρ = 0.23, b)
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measurement of apoA1 and apoB does not provide additive 
clinical value over traditional lipid levels [4]. LPA has a 
similar structure to LDL; however, it contains a unique 
apolipoprotein, the apolipoprotein (a). It may pose further 
risk for cardiovascular disease in subjects with family his-
tory of thromboembolic events [4].
Studies investigating serum lipid profile in OSA are con-
tradictory. In general, reports finding no association analysed 
data from a limited number of subjects [27]. However, in 
case–control studies recruiting many volunteers, the rela-
tionship between OSA severity and lipid levels was signifi-
cant, but it was also weak [6, 7] and non-linear [2]. A meta-
regression analysis by Nadeem et al. concluded that OSA 
is associated with high total cholesterol, LDL-C and TG 
and low HDL-C [28]. Nevertheless, even if a study did not 
find a difference in lipid or apolipoprotein concentrations, 
dysfunctionality of HDL was reported, suggesting qualita-
tive rather than quantitative alterations in lipid profile [29]. 
A study involving more than 500 subjects demonstrated a 
direct relationship between AHI and apoB levels but no rela-
tionship with apoA1 [30]. On contrary, Guan et al. reported 
a direct relationship with apoB and an indirect association 
with apoA1 in nearly 3000 volunteers [2]. Considering all 
previous data, the difference in serum lipid and apoprotein 
concentrations between the OSA and control groups is small 
and may be statistically significant only when increasing 
the number of subjects [28]. We found a significant differ-
ence in TG, HDL-C and ApoB, while ApoA1 tended to be 
lower in OSA. Interestingly, there was a significant associa-
tion between markers of hypoxaemia and LDL-C as well as 
total cholesterol, while these lipids did not relate to AHI or 
ODI. These confirm the previous data that hypoxia is more 
strongly related to dyslipidaemia than to the apnoeic periods 
[7, 30]. In line with previous reports [2], LPA levels were 
unaltered in OSA in the current study. Confirming the recent 
data on the association between systemic inflammation and 
dyslipidaemia in OSA [31], lipid markers except for ApoA1 
and LPA correlated with CRP.
Although animal models show that chronic intermittent 
hypoxia and sleep fragmentation may independently induce 
lipid dysfunction [1], this has not been confirmed by the 
present study. Only LDL-C correlated with arousal index, 
suggesting that a more fragmented sleep is associated with 
lower LDL-C. These surprising associations need to be con-
firmed in an independent cohort.
The significance of obesity as a covariate is frequently 
disputed [1]. In experimental OSA models, dyslipidaemia 
was induced in non-obese animals [1], and in some human 
studies the relationship between OSA severity and dyslipi-
daemia existed even after adjustment for BMI [2, 7, 30]. A 
recent study involving more than 8000 participants reported 
that paradoxically, morbid obesity may be associated with 
lower TG and higher HDL-C [7]. As OSA severity is directly 
related to BMI [32], obesity is likely to be a bias for the 
relationship between OSA and lipids. In the current work, 
similarly to a recent study conducted on 2983 patients [2], 
obesity was found to be a significant covariate; however, the 
extent of its effect needs to be estimated in larger cohorts. 
Of note, the relationship between obesity and OSA is bidi-
rectional. On one hand, obesity worsens OSA by inducing 
accumulation of fat tissue around upper airways and influ-
encing ventilatory control [33]. On the other hand, sleep 
fragmentation promotes hyperphagia and increases the 
number and size of adipocytes, while chronic intermittent 
hypoxia induces lipolysis and inflammation in fat tissue [1]. 
Nevertheless, after the adjustment for BMI, all correlations 
between OSA severity and lipid markers became insignifi-
cant. Waist circumference may a better estimate for obesity 
than BMI [34]. However, we have not measured that in this 
study.
The lipid profile shows geographic, racial, gender- and 
age-related variability [34]. In addition, OSA is more 
Fig. 2  Relationship between serum HDL-C levels and  AHIREM (a) as well as  AHINREM (b). There was no correlation between HDL-C and 
 AHIREM (p > 0.05, a), while there was a significant relationship between HDL-C and  AHINREM (p < 0.01, ρ = − 0.32, b)
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strongly related to metabolic syndrome in younger age [35]. 
However, adjustment for age influenced our results only mar-
ginally, while only the relationships between AHI and TG 
remained significant after adjustment for gender.
Because of the prominent effect of BMI, the conclusions 
on  AHIREM as well as  AHINREM need to be interpreted care-
fully. Previous studies finding  AHIREM dependence of hyper-
tension and insulin resistance concluded that the prominent 
effect of REM sleep may be due to increased sympathetic 
tone [14–16, 19]. In fact, increased sympathetic activity 
may induce lipolysis liberating circulating lipids [3]. How-
ever, it seems that this effect is marginal in OSA as non-
REM-related sleep disturbances were more closely related 
to dyslipidaemia. This is in line with the previous results 
showing that although CPAP reduces sympathetic activity, 
it has only a minor effect on the metabolic profile [36]. Apart 
from the sympathetic activity, significant sleep phase-related 
differences exist also in the production of hormones which 
may affect lipid metabolism. It is known that GH is mainly 
produced during stage N3 sleep [20] and OSA is associated 
with decreased levels of GH [12]. Exogenous GH has been 
reported to increase HDL-C in growth hormone-deficient 
patients [37] suggesting a direct relationship between GH 
and HDL-C. Additionally to intermittent hypoxia and sleep 
fragmentation, the increased production of free fatty acids 
in OSA may itself decrease GH production [12]. The release 
of another hormone, the thyrotropin also peaks during early, 
non-REM dominant stages of sleep with a significant reduc-
tion during sleep deprivation [11]. The resulting hypothy-
roidism may lead to hyperlipidaemia even at subclinical 
stages [38]. Reduction in the levels of GH and thyrotropin 
during disturbed non-REM sleep may explain our findings. 
However, this needs to be confirmed by simultaneous meas-
urement of hormones and lipids.
Studies finding differences in REM versus non-REM 
OSA in the risk for cardiovascular disease, hypertension and 
diabetes had important clinical implications about the effect 
of CPAP compliance on comorbidities [14–16, 19]. Theo-
retically, because REM phase occurs predominantly during 
the latter stages of sleep, too short (< 4 h) CPAP usage at 
the beginning of sleep may have markedly lesser beneficial 
effect on comorbidities. Dorkova et al. compared the effect 
of 8-week CPAP treatment on lipid profile in patients who 
daily used their device for more or less than 4 h [39]. Longer 
CPAP usage had significantly greater effect on total choles-
terol, TG, LDL-C and apoB, while no difference was seen 
on ApoB1 and HDL-C [39]. Although our findings suggest 
that non-REM sleep has a more pronounced effect on lipid 
profile, it should still be recommended to use CPAP as long 
as possible due to two reasons. Firstly, our study did not dif-
ferentiate between early and late night non-REM sleep, and 
secondly, REM sleep was also significantly associated with 
lipid profile, however less strongly than non-REM.
In summary, we found that AHI during REM is as 
strongly associated with dyslipidaemia as obstructive events 
in non-REM sleep. Our findings may at least partly explain 
previous contradictions between studies analysing lipids and 
apolipoproteins in OSA and may facilitate further research.
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